Pyxus Strikes Creditor Deal: ~$92M Debt-to-Equity Swap, $85M Equity Raise, Maturities Extended
PYYX sits 23% above its 52-week low of $2 on elevated volume (2.3× avg).
Summary
Pyxus signed a transaction support agreement with creditors holding a majority of its term loans and 2027 notes to exchange roughly $92 million of debt into equity, raise up to $85 million of new stock at $2.50, and extend about $300 million of maturities to 2031 — heavily diluting existing holders and still subject to 99% participation and a December 15, 2026 closing deadline.
Key Events · Financing and Capital Events · PYYX
-
Creditor-Backed Restructuring Agreement Signed
Supporting holders representing approximately 74.9% of Pyxus Term Loans, 67.9% of Intabex Term Loans and 56.0% of the 8.50% Senior Secured Notes due 2027 agreed to back exchange transactions.
-
Debt Cut by ~$92M, $65M Paid Down
If consummated in full, the exchanges convert approximately $92,000,000 of debt into equity, pay down $65,000,000 from equity offering proceeds, and extend maturities on roughly $300,000,000 of remaining secured debt to December 31, 2031.
-
Up to 71.4M New Shares at $2.50-$3.25
Pyxus will issue up to 71,405,139 shares for up to $199,854,206: 34,000,000 shares in the $85,000,000 equity offering at $2.50, 28,455,139 shares in the debt exchanges at $3.25, and 8,950,000 shares for the $22,375,000 of premiums and early signing payment at $2.50.
-
99% Participation and ABL Consent Required
Closing requires holders of at least 99% of each of the Existing Notes, Pyxus Term Loans and Intabex Term Loans to participate (waivable; notes threshold reducible to 97%), plus ABL lender consent and concurrent completion of all transactions.
Analysis · PYYX · Trade & Services
Pyxus has locked in support from creditors holding roughly three-quarters of its term loans and over half its 2027 notes for a restructuring that converts about $92 million of debt into equity, pays down $65 million with proceeds of a new $85 million stock sale, and pushes out maturities on the remaining ~$300 million to 2031. That materially reduces the liquidity risk flagged in the same-day 10-Q, where $1.35 billion of debt included $890.8 million of short-term notes payable against $96.6 million of cash. Existing shareholders bear the cost: up to 71.4 million new shares will be issued at $3.25 (debt exchange) and $2.50 (equity offering), against a $2.45 last trade, and the equity offering is a private placement with no registration rights, so retail holders cannot participate. The deal is not done — it needs 99% participation in each debt tranche (waivable, notes floor 97%), ABL lender consent, and must close by December 15, 2026 or the support agreement can terminate.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PYYX was trading at $2.45 on OTC in the Trade & Services sector, with a market capitalization of approximately $60.3M. The 52-week trading range was $2.00 to $6.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.